Clinical Trial Update: Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab, carboplatin, gemcitabine, and atezolizumab in metastatic triple-negative breast cancer; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Metastatic Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN